Viking Net Debt from 2010 to 2024

VKTX Stock

USD 54.51 1.09 2.04%

Viking Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2024. Net Debt is the total debt of Viking Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2014-03-31

Previous Quarter

-42.8 M

Current Value

-49.1 M

Quarterly Volatility

39.6 M

Yuan Drop

Covid

Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K or Selling General Administrative of 38.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.29. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.

Check out the analysis of Viking Therapeutics Correlation against competitors.

For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Viking Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Viking Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Viking Net Debt Regression Statistics

	Arithmetic Mean	(15,425,477)
	Geometric Mean	2,195,614
	Coefficient Of Variation	(128.36)
	Mean Deviation	17,092,445
	Median	(5,537,938)
	Standard Deviation	19,800,320
	Sample Variance	392.1T
	Range	55.6M
	R-Value	(0.89)
	Mean Square Error	89.7T
	R-Squared	0.79
	Significance	0.00001
	Slope	(3,928,904)
	Total Sum of Squares	5488.7T

Viking Net Debt History

	2024	-51.5 M
	2023	-54.3 M
	2022	-35.1 M
	2021	-26.3 M
	2020	-28.8 M
	2019	-7.7 M
	2018	-24.8 M

Other Fundumenentals of Viking Therapeutics

Net Debt To E B I T D A

Viking Therapeutics Net Debt component correlations

	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Total Assets	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Treasury Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Stockholder Equity		-0.87	-0.82	0.67	0.31	0.88	1.0	1.0	-0.23	0.88	-0.83	-0.66	0.68	0.95	-0.61	0.9	-0.11	0.98	0.98	-0.61
Net Debt	-0.87		0.96	-0.87	-0.51	-0.79	-0.89	-0.88	0.15	-0.65	0.74	0.59	-0.62	-0.76	0.71	-0.84	0.1	-0.82	-0.82	0.71
Retained Earnings	-0.82	0.96		-0.92	-0.59	-0.78	-0.84	-0.84	0.03	-0.61	0.78	0.67	-0.69	-0.7	0.7	-0.83	0.0	-0.77	-0.77	0.7
Accounts Payable	0.67	-0.87	-0.92		0.72	0.64	0.7	0.7	-0.01	0.45	-0.63	-0.53	0.54	0.54	-0.66	0.69	-0.03	0.6	0.61	-0.66
Total Liab	0.31	-0.51	-0.59	0.72		0.44	0.36	0.35	0.05	0.25	-0.4	-0.34	0.39	0.31	-0.24	0.46	0.02	0.34	0.34	-0.24
Common Stock	0.88	-0.79	-0.78	0.64	0.44		0.88	0.88	-0.16	0.93	-0.91	-0.74	0.83	0.93	-0.24	0.99	0.07	0.92	0.93	-0.24
Total Assets	1.0	-0.89	-0.84	0.7	0.36	0.88		1.0	-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Total Current Assets	1.0	-0.88	-0.84	0.7	0.35	0.88	1.0		-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Short Term Debt	-0.23	0.15	0.03	-0.01	0.05	-0.16	-0.22	-0.22		-0.22	-0.16	-0.46	0.4	-0.29	0.01	-0.26	0.83	-0.28	-0.28	0.01
Net Tangible Assets	0.88	-0.65	-0.61	0.45	0.25	0.93	0.88	0.88	-0.22		-0.88	-0.7	0.75	0.94	-0.18	0.91	0.0	0.92	0.93	-0.18
Current Deferred Revenue	-0.83	0.74	0.78	-0.63	-0.4	-0.91	-0.84	-0.84	-0.16	-0.88		0.94	-0.94	-0.81	0.32	-0.88	-0.25	-0.82	-0.83	0.32
Deferred Long Term Liab	-0.66	0.59	0.67	-0.53	-0.34	-0.74	-0.66	-0.66	-0.46	-0.7	0.94		-0.95	-0.62	0.27	-0.68	-0.45	-0.64	-0.64	0.27
Short Long Term Debt	0.68	-0.62	-0.69	0.54	0.39	0.83	0.69	0.69	0.4	0.75	-0.94	-0.95		0.7	-0.19	0.77	0.52	0.7	0.7	-0.19
Short Term Investments	0.95	-0.76	-0.7	0.54	0.31	0.93	0.94	0.94	-0.29	0.94	-0.81	-0.62	0.7		-0.35	0.93	-0.11	0.99	0.99	-0.35
Long Term Debt Total	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35		-0.32	0.17	-0.45	-0.45	1.0
Capital Surpluse	0.9	-0.84	-0.83	0.69	0.46	0.99	0.9	0.9	-0.26	0.91	-0.88	-0.68	0.77	0.93	-0.32		-0.05	0.94	0.94	-0.32
Treasury Stock	-0.11	0.1	0.0	-0.03	0.02	0.07	-0.11	-0.11	0.83	0.0	-0.25	-0.45	0.52	-0.11	0.17	-0.05		-0.12	-0.12	0.17
Net Invested Capital	0.98	-0.82	-0.77	0.6	0.34	0.92	0.97	0.97	-0.28	0.92	-0.82	-0.64	0.7	0.99	-0.45	0.94	-0.12		1.0	-0.45
Net Working Capital	0.98	-0.82	-0.77	0.61	0.34	0.93	0.97	0.97	-0.28	0.93	-0.83	-0.64	0.7	0.99	-0.45	0.94	-0.12	1.0		-0.45
Capital Stock	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35	1.0	-0.32	0.17	-0.45	-0.45

Click cells to compare fundamentals

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-54.3 M	-51.5 M
Net Debt To EBITDA	0.54	0.57

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viking Net Debt from 2010 to 2024

Latest Viking Therapeutics' Net Debt Growth Pattern

Viking Net Debt Regression Statistics

Viking Net Debt History

Other Fundumenentals of Viking Therapeutics

Viking Therapeutics Net Debt component correlations

About Viking Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Viking Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY